

No: 03.../TKKT

Ho Chi Minh City, January 20, 2025

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Subject: Explanation of the business results for Quarter and the full year 2024 with a discrepancy of more than 10% compared to the same period in 2023

Pursuant to the regulations under Circular 96/2020/TT-BTC on public disclosure in the securities market, Mekophar Chemical and Pharmaceutical Joint Stock Company (Stock code: MKP) provides an explanation of the business results for Quarter and the full year 2024 with a difference of more than 10% compared to the same period in 2023 as follows::

1. Results for Quarter 2024 compared to Quarter 2023 (Separate Report):

Indicator	Quarter 2024	Quarter 2023	Difference	(%)
Revenue	240.846.477.394	246.998.010.675	- 6.151.533.281	-2,5%
Cost of Goods Sold	168.330.045.819	165.478.206.411	2.851.839.408	1,7%
Selling Expenses	26.208.346.189	27.987.077.531	- 1.778.731.342	-6,4%
Administrative Expenses	34.340.924.230	44.736.312.670	- 10.395.388.440	-23,2%
Financial Revenue	37.866.472.868	13.490.826.101	24.375.646.767	180,7%
Net Profit After Tax	28.885.148.995	17.654.619.937	11.230.529.058	63,6%

Reason: The net profit after tax for Quarter 2024 increased by 63.6% mainly due to income from financial investments.

2. Results for 2024 compared to 2023 (Separate Report):

Indicator	Quarter 2024	Quarter 2023	Difference	(%)
Revenue	906.539.383.047	891.944.222.392	14.595.160.655	1,6%
Cost of Goods Sold	632.938.992.151	600.641.362.143	32.297.630.008	5,4%
Selling Expenses	110.210.557.762	108.463.534.736	1.747.023.026	1,6%
Administrative Expenses	120.567.244.506	126.828.659.552	- 6.261.415.046	-4,9%
Financial Revenue	65.661.338.650	22.365.139.951	43.296.198.699	193,6%
Net Profit After Tax	42.263.025.646	25.114.127.514	17.148.898.132	68,3%

Reason: The net profit after tax for 2024 increased by 68.3% mainly due to income from financial investments.

This information has been published on the Company's website at: <https://mekophar.com/> in the "Investor Relations" section.

The Company affirms that the information provided is accurate and takes full responsibility for the disclosed content.

Recipient:

- As above
- Archive



Pharm. Huỳnh Thị Lan